Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspiration risk during sedation with remifentanil versus dexmedetomidine
ACTRN12611000794909Phase 3Not yet recruiting
- Sponsor
- Dr Islam Elhalawani
- Start
- Sep 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of remifentanil and dexmedetomidine, sponsored by Dr Islam Elhalawani. Primary endpoints: Oesophageal motor activity, Oesophageal motility and reflux by impedance and 1 more. Planned start Sep 2011; status: not yet recruiting.
02
Drugs
remifentanildexmedetomidine
Beyond the preview
Go deeper on ACTRN12611000794909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000794909.